Tirzepatide and B12: what does the evidence show?

What the SURMOUNT trial data tells us about nutrition on tirzepatide

In SURMOUNT-1, adults taking tirzepatide at the highest dose achieved an average body-weight reduction of around 20–21% over 72 weeks, published in the New England Journal of Medicine. A weight loss of that magnitude almost always reflects a substantial and sustained reduction in calorie intake. For most people, that means eating considerably less across the board, including foods that are the primary dietary sources of vitamin B12: meat, fish, eggs and dairy.

The SURMOUNT programme did not report clinically significant B12 deficiency as a treatment-emergent adverse event. That matters. It tells us tirzepatide is not interfering with intrinsic factor or the ileal absorption pathway the way some medications do. But it does not mean nutrition looks after itself. A person eating 30–40% fewer calories per day over many months is simply consuming less of almost every micronutrient, B12 included.

This is not a reason to avoid treatment. It is a reason to pay attention to what you eat on treatment, particularly protein and nutrient-dense foods, and to keep routine health checks in place. Our clinical team recommends treating the medicine and nutritional awareness as two parts of the same plan, not separate concerns.

Why B12 specifically deserves attention during weight loss treatment

B12 is unusual among vitamins because the body stores it in the liver, typically enough for several years. That means deficiency develops slowly and quietly. By the time symptoms appear, such as persistent fatigue, pins and needles in the hands or feet, difficulty concentrating or low mood, levels may have been falling for months. Those symptoms can be easy to dismiss or to attribute to something else entirely.

There is a common misconception that tiredness on a GLP-1 or GIP/GLP-1 medicine is simply the body adjusting. Sometimes it is. But fatigue that persists beyond the first few weeks of treatment, or that returns after initially settling, is always worth investigating properly rather than waiting out. Low B12 is one of several things a routine blood panel can rule in or out quickly. You can read more about how tirzepatide works in the body on the tirzepatide overview page.

People following a very low-calorie or predominantly plant-based diet while on treatment carry a higher theoretical risk, since plant foods contain little or no B12. If that describes you, mentioning it to your prescriber is worthwhile, and if you are also managing a long-term neurological condition it is worth reading about tirzepatide and MS before your next review. A daily B12 supplement is inexpensive, very safe and widely available; whether you need one and at what dose is a clinical decision rather than something to guess at. The NHS medicines page for tirzepatide covers general dietary guidance in the context of this treatment.

How this compares to the metformin-B12 relationship

It is worth being precise here, because the two situations are genuinely different. Metformin reduces B12 absorption through a specific mechanism involving calcium-dependent membrane activity in the ileum. That effect is well-documented, dose-dependent and the reason B12 monitoring is now built into standard diabetes management. People often start tirzepatide having previously taken metformin, or still taking it alongside tirzepatide for type 2 diabetes, and carry assumptions from one medicine across to the other.

Tirzepatide does not share that mechanism. As a dual GIP and GLP-1 receptor agonist, its action is on appetite signalling and gastric motility, not on gut absorption pathways for micronutrients. For a fuller explanation of how the medicine is used in the UK, the Mounjaro information page is a good starting point. If you are currently on metformin alongside tirzepatide, B12 monitoring is relevant to both treatments and your prescriber should be factoring both in.

If you are thinking about the cost and practicalities of private treatment alongside these health considerations, the weight-loss treatment overview gives a clear picture of what a supported programme actually involves.

Practical steps: monitoring, diet and talking to your prescriber

Blood tests are the only reliable way to know where your B12 stands. Symptoms alone are not a good guide, since the overlap with other common complaints is significant. A baseline check before or early in treatment, and a repeat at around six months, gives you something to compare. If you are taking hormone replacement therapy at the same time, it is also worth understanding how HRT and tirzepatide interact before interpreting any blood results. This can be arranged through your GP or as part of your ongoing clinical review.

On the dietary side, prioritising protein at most meals serves two purposes: it helps preserve muscle during weight loss and it tends to bring B12-rich foods along with it. Eggs at breakfast, fish a few times a week, lean meat or dairy when appetite allows. None of this needs to be complicated. More detail on the interaction between tirzepatide and nutritional factors is covered on the B12 and Mounjaro page.

If you have a medical condition that already affects B12 metabolism, or you are on other medicines that interact with absorption, make sure your prescriber knows. The frequently asked questions page covers a range of practical queries that come up during treatment, and if you want to explore the full range of dose options available the tirzepatide L page sets out what is on offer. And if something specific is worrying you between reviews, the support team is available seven days a week.

Tirzepatide is a prescription-only medicine. A GPhC-registered prescriber at nume reviews every consultation personally before any treatment is issued. If you are considering whether this treatment is right for you, check your eligibility with a free consultation.